Artificial Intelligence driven Marketing Communications
NEW YORK, — Pomerantz LLP is investigating claims on behalf of investors of Indivior PLC (“Indivior” or the “Company”) (OTCMKTS: INVVY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
The investigation concerns whether Indivior and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On April 9, 2019, the U.S. Department of Justice (“DOJ”) announced that a federal grand jury had indicted Indivior “for engaging in an illicit nationwide scheme to increase prescriptions of Suboxone Film, an opioid drug used in the treatment of opioid addiction.” The DOJ stated that “[a]ccording to the indictment, Indivior obtained billions of dollars in revenue from Suboxone Film prescriptions by deceiving health care providers and health care benefit programs into believing that Suboxone Film was safer, less divertible, and less abusable than other opioid-addiction treatment drugs.” Following news of Indivior’s indictment, the Company’s American depositary receipt price fell $4.48 per share, or 66.08%, to close at $2.30 per share on April 10, 2019.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com